Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 510

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence

Open access
Coombes, Raoul Charles, Page, Karen, Salari, Raheleh, Hastings, Robert K., Armstrong, Anne, Ahmed, Samreen, Ali, Simak, Cleator, Susan, Kenny, Laura, Stebbing, Justin, Rutherford, Mark, Sethi, Himanshu, Boydell, Anna, Swenerton, Ryan, Fernandez-Garcia, Daniel, Gleason, Kelly L.T., Goddard, Katie, Guttery, David S., Assaf, Zoe J., Wu, Hsin-Ta, Natarajan, Prashanthi, Moore, David A., Primrose, Lindsay, Dashner, Scott, Tin, Antony S., Balcioglu, Mustafa, Srinivasan, Ramya, Shchegrova, Svetlana V., Olson, Alexander, Hafez, Dina, Billings, Paul, Aleshin, Alexey, Rehman, Farah, Toghill, Bradley J., Hills, Allison, Louie, Maggie C., Lin, Cheng-Ho Jimmy, Zimmermann, Bernhard G., Shaw, Jaqueline A.·2019·Clinical Cancer Research

Abstract

Purpose: Up to 30% of patients with breast cancer relapse after primary treatment. There are no sensitive and reliable tests to monitor these patients and detect distant metastases before overt recurrence. Here, we demonstrate the use of personalized circulating tumor DNA (ctDNA) profiling for detection of recurrence in breast cancer. Experimental Design: Forty-nine primary patients with breast cancer were recruited following surgery and adjuvant therapy. Plasma samples (n = 208) were collected every 6 months for up to 4 years. Personalized assays targeting 16 variants selected from primary tumor whole-exome data were tested in serial plasma for the presence of ctDNA by ultradeep sequencing (average >100,000X). Results: Plasma ctDNA was detected ahead of clinical or radiologic relapse in 16 of the 18 relapsed patients (sensitivity of 89%); metastatic relapse was predicted with a lead time of up to 2 years (median, 8.9 months; range, 0.5–24.0 months). None of the 31 nonrelapsing patients were ctDNA-positive at any time point across 156 plasma samples (specificity of 100%). Of the two relapsed patients who were not detected in the study, the first had only a local recurrence, whereas the second patient had bone recurrence and had completed chemotherapy just 13 days prior to blood sampling. Conclusions: This study demonstrates that patient-specific ctDNA analysis can be a sensitive and specific approach for disease surveillance for patients with breast cancer. More importantly, earlier detection of up to 2 years provides a possible window for therapeutic intervention.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-18-3663

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 510

Metadata

Authors
Coombes, R. C., Page, K., Salari, R., Hastings, R. K., Armstrong, A., Ahmed, S., Ali, S., Cleator, S., Kenny, L., Stebbing, J., Rutherford, M., Sethi, H., Boydell, A., Swenerton, R., Fernandez-Garcia, D., Gleason, K. L. T., Goddard, K., Guttery, D. S., Assaf, Z. J., Wu, H.-T., Natarajan, P., Moore, D. A., Primrose, L., Dashner, S., Tin, A. S., Balcioglu, M., Srinivasan, R., Shchegrova, S. V., Olson, A., Hafez, D., Billings, P., Aleshin, A., Rehman, F., Toghill, B. J., Hills, A., Louie, M. C., Lin, C.-H. J., Zimmermann, B. G., & Shaw, J. A.
Venue
Clinical Cancer Research
Published
2019-07-15
Volume
25
Issue
14
Pages
4255-4263
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2939548416
Cited by
510
References
32
FWCI
13.48
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-18-3663
The paper
Coombes, R. C., Page, K., Salari, R., Hastings, R. K., Armstrong, A., Ahmed, S., Ali, S., Cleator, S., Kenny, L., Stebbing, J., Rutherford, M., Sethi, H., Boydell, A., Swenerton, R., Fernandez-Garcia, D., Gleason, K. L. T., Goddard, K., Guttery, D. S., Assaf, Z. J., . . . Shaw, J. A. (2019). Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-18-3663

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.